$16.97
Codexis
Performance
Dividends
1W
1M
YTD
1Y
3Y
About
Codexis is a leading enzyme engineering company which discovers and develops novel, high performance enzymes and biotherapeutics
Twitter
Web
Share
27/36
Growth
Score
9/36
Dividend
Score
Valuation
PE Ratio
-51.77
PS Ratio
10.52
3
RSI
41.25
3
PEG Ratio
0.01
3
PRG Ratio
0.03
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
127%
3
Gross Margin
78.8%
3
Current Ratio
4.85
Return on Assets
-8.64%
Return on Equity
-12.9%
Return on inv. Capital
-10.66%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2021 104.75M
2014
2015
2016
2017
2018
2019
2020
2021
7
Net Income 2021 -21.28M
2014
2015
2016
2017
2018
2019
2020
2021
7
Gross Profit 2021 82.55M
2014
2015
2016
2017
2018
2019
2020
2021
7
What will move the market
These are the numbers that will move the market, and the guidance that will move it as well.
-$0.19
99.64% YoY
EPS
28.73M
91.00% YoY
Revenue
Current Quarter Analyst Estimates
-$0.11
99.43% YoY
EPS
40.33M
NaN% YoY
Revenue
Next Quarter Analyst Estimates
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
22.04.2010
MaketCap
1.10B
Country
US
CEO
Mr. John Nicols
Description
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Updated 15.03.2022